Procoagulant role of neutrophil extracellular traps in patients with gastric cancer

Chunfa Yang, Wenying Sun, Wu Cui, Xingku Li, Jialin Yao, Xuanye Jia, Changjian Li, Hongjie Wu, Zhaoyang Hu, Xiaoming Zou

Departments of Gastrointestinal Surgery, Clinical Laboratory Services, Research Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China; Department of General Surgery of The First Hospital of Harbin, Harbin, China

Received September 6, 2015; Accepted October 12, 2015; Epub November 1, 2015; Published November 15, 2015

Abstract: Background: Patients with gastric cancer (GC) commonly exhibit a hypercoagulable state that results in significant morbidity and mortality. Recent studies have shown that neutrophil extracellular traps (NETs) trigger coagulation through an intrinsic pathway and contribute to thrombus initiation and progression. In this study, we aimed to determine the procoagulant activity (PCA) of NETs in patients with GC. Methods: NET formation and their PCAs were assessed in 48 patients with GC and 36 healthy controls using immunofluorescence microscopy of neutrophil markers and extracellular DNA as well as a modified capture ELISA technique, and thrombin-antithrombin complex and clot (fibrin) spectroscopic detection, respectively. Results: Here we showed that neutrophils isolated from patients with GC displayed significantly enhanced NET formation compared with those from healthy controls; furthermore, plasma or platelets obtained from patients with GC induced control neutrophils to release NETs. In addition, NETs released by GC neutrophils significantly increased the potency of control plasma to generate thrombin and fibrin. Notably, these procoagulant effects were dramatically attenuated by application of DNase I. We further found that spontaneous NET formation in patients with GC was significantly higher than that in controls, increased with tumor-node-metastasis stage elevation, and positively correlated with thrombin-antithrombin complex levels and D-dimers. Additionally, the effect of DNase I on cell-free plasma generation of fibrin was dependent on the concentration of NET formation. Conclusion: These results suggest that GC creates a systemic environment that primes neutrophils to release procoagulant NETs. Thus, targeting NETs might improve the coagulopathy of patients with GC.

Keywords: Stomach neoplasm, prothrombotic state, neutrophils, NETs, cell-free DNA

Introduction

A hypercoagulable state is a common complication and a major contributor to morbidity and mortality in patients with gastric cancer as the activation of coagulation promotes tumor growth and metastasis and increases the risk of venous thrombosis, which is the second leading cause of death in these patients [1-10]. On the other hand, thromboprophylaxis, the prophylactic employment of anticoagulation therapies, in patients with cancer has a strong potential to limit the risk of thrombosis, translating into improved patient survival [11, 12]. However, anticoagulant use in these patients remains a significant challenge owing to the unequal distribution of venous thrombosis incidence among patients and the high risk of bleeding related with anticoagulant treatment [5-7, 13, 14]. Therefore, a better understanding of the pathogenesis of the hypercoagulable state in patients with cancer is urgently needed.

Recently, neutrophil extracellular traps (NETs), generated from activated neutrophils and composed of cell-free DNA, histones, and granular and cytoplasmic neutrophil proteins, have been shown to offer a novel mechanism for promoting coagulation and thrombosis and are viewed as a link between interfile inflammation and thrombosis [14-18]. Cell-free DNA promotes coagulation activation through an intrinsic pathway [18] and histones induce platelet and erythrocyte activation, which triggers coagulation [19, 20]. Notably, inflammation is a hallmark of cancer [21, 22], and activated neutrophils play a vital role in the thrombosis...
NETosis in gastric cancer

associated with cancer in mouse [23, 24]. Furthermore, Demers et al. recently found that 
NET formation increased and consequently induced the prothrombotic state in mice with cancer [24]; in addition, NET formation has been found to induce organ dysfunction associated with cancer in a very recent animal study [25]. In this context, we hypothesized that NET formation increases and then contributes to a hypercoagulable state in patients with gastric cancer. Accordingly, we assessed the ability of the circulation environment of patients with gastric cancer to prime neutrophils to release NETs, and investigated the contribution of NETs to coagulation in these patients. The current results led us to believe that gastric cancer primes neutrophils to release NETs, which, in turn, play a role in coagulation activation in patients with gastric cancer.

Patients and methods

Patients

In this prospective study, pretreatment blood samples were collected from 48 consecutive patients with gastric cancer admitted to the Department of Gastrointestinal Surgery in the Second Affiliated Hospital of Harbin Medical University of China, between April 2015 and August 2015. Histological classification and pathologic tumor-node-metastasis (TNM) staging were assessed according to the 7th American Joint Committee on Cancer (AJCC). Numbers of neutrophils and D-dimers were determined in the hospital's routine laboratories. Thirty-six healthy volunteers were recruited from among the hospital staff as healthy controls. Exclusion criteria were age < 18 years, active or chronic infection, cardiovascular disease, diabetes, liver or renal dysfunction, other coexisting cancer, thromboembolic complications, platelets and/or blood coagulation disorders, and administration of anticoagulant and/or antiplatelet treatment. Informed consent was obtained from each patient and control. The study was approved by the Ethics Committee of Harbin Medical University and conducted in accordance with the principles enshrined in the Declaration of Helsinki.

Preparation of platelet rich plasma (PRP), platelet free plasma (PFP), platelets, and neutrophils

Fresh whole venous blood samples were collected with a 21-gauge needle into 3.2% sodium citrate the morning after overnight fasting, and centrifuged (10 min, 150 g) at room temperature to obtain PRP [17]. PFP was prepared with two serial centrifugations (2500 g for 15 min, twice) and stored in aliquots at -80°C until used, as previously described [26, 27]. Platelets were isolated immediately from PRP with centrifugation (10 min, 600 g), and then washed and resuspended in HEPES buffer, and used for the in vitro study [17]. Neutrophils were obtained through density gradient centrifugation with Percoll according to the manufacturer’s instructions, followed by hypotonic lysis as described previously [24]. Neutrophil purity (> 98%) was assessed by Wright-Giemsa staining and viability (> 98%) by Trypan blue stain.

In-vitro NET formation

Purified neutrophils (1 × 10⁶) isolated from patients with GC or healthy controls were subsequently incubated for 3 hours at 37°C in 5% CO₂. For in vitro studies, neutrophils from control individuals (n = 5) were treated with 6% plasma isolated from patients (n = 48) or from control individuals (n = 36) or with PBS, or treated with platelets derived from patients with GC (n = 10) or from control individuals in a ratio of 1:50 for 3 hours (n = 10). Then, the supernatants were collected by centrifugation (10 min, 1500 g) [18], and cell-free DNA (CFDNA) was quantified with fluorescence quantification, as described previously [28, 29]. Briefly, 50 μl samples were mixed with 50 μl SytoxGreen (final concentration 2 M; Invitrogen, Carlsbad, CA, USA) to label the DNA. Fluorescence was recorded with a Spectramax microplate fluorometer (TECAN Infinite M 200, TECAN, San Jose, CA, USA) at 485 nm excitation and 538 nm emission. DNA concentrations were calculated based on a standard curve of known concentrations of DNA (Invitrogen).

Immunofluorescence

To further visualize NET formation, neutrophils with and without stimulation were seeded into 24 wells (coated with poly-L-lysine) at 37°C in the presence of 5% CO₂ for 3 hours. Cells were fixed with 4% paraformaldehyde and stained using a mouse anti-myeloperoxidase (MPO) mAb (1/100, Wanleibio, Shenyang, China) and an IgG1 anti-CD19 mAb (1/200, DAKO, Glostrup, Denmark) was utilized as an isotype control. A polyclonal rabbit anti-mouse Alexa fluor 647 (1/100 dilution, ZSGB-BIO, Beijing,
NETosis in gastric cancer

China) were utilized as secondary antibodies. SytoxGreen was used for DNA counterstaining. Visualization was performed in a Nikon ECLIPSE Ti microscope (Tokyo, Japan). Data were expressed as the percentage of NET-forming cells in relation to the total number of cells [17].

Measurement of NET procoagulant activity using the thrombin and fibrin generation test

To assess NET procoagulant activity, we performed a thrombin and fibrin generation test. Thrombin generation was assessed using the thrombin-antithrombin complex (TAT), as previously described [17]. Briefly, 80 l plasma obtained from patients or controls or control plasma stimulated in vitro with NET structures (in a final concentration of 20%) was incubated with PBS (5 l), or DNase I (400 µg/ml, 5 l) for 30 minutes at 37°C in a 96-well plate [18]. Clotting was initiated by addition of CaCl2 (15 l; 0.1 M). The reaction was performed for 5 minutes at 37°C. To stop the reaction, samples were immediately transferred in ice. TAT was measured according to manufacturer instructions (BlueGene, Shanghai, China). To further assess the NET procoagulant role, we performed a fibrin generation test as previously described [31-33]. Fibrin (clot) formation was continually monitored by measuring the optical density (405 nm) of the plasma on a Spectramax microplate reader at 37°C for 1 hour.

Quantification of autonomous NET formation in patients with GC

To quantify NET formation in patients with GC, we measured the amount of circulating myeloperoxidase (MPO)-DNA complex, a well-established marker of NET formation, using a modified capture ELISA technique as previously described [17, 33, 34]. In addition, nucleosome (Roche Diagnostics GmbH, Mannheim, Germany) and neutrophil elastase (NE) (BlueGene, Shanghai, China) were measured using ELISA kits according to the manufacturers’ instructions, and CFDNA was tested as described above.

Statistical analysis

Continuous variables were presented as means ± standard deviation (SD). A T test was used for quantitative data, the least significant difference (LSD) method was used for multiple comparisons, the Kal-Wallis test for ordered variables, and Spearman’s rank correlation analysis for the correlation between continuous variables. Paired t-tests were performed for paired sample analyses. Statistical significance was set as P-values of 0.05 or less. SAS9.2 software (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis.

Results

Characteristics of patients and healthy controls

Forty-eight patients with GC, including 7 at stage I, 9 stage II, 25 stage III, and 7 at stage IV along with 36 healthy controls were enrolled in this study. The characteristics of patients and healthy subjects are summarized in Table 1. There were no significant differences in the means of age, sex, and neutrophil counts between patients and healthy controls. However, plasma TAT and D-dimer levels in

| Table 1. Clinical and demographic characteristics of study subjects |
|-------------------|----------------|----------------|
| Variable          | CTR            | GC             | P value |
| Sex (M/F)         | 24/12          | 35/13          | 0.541   |
| Age (years)       | 56.1 ± 9.2     | 55.9 ± 9.6     | 0.2066  |
| Neutrophils (10⁶/l) | 3.46 ± 1.04   | 3.94 ± 1.31    | 0.68    |
| TAT (pg/ml)       | 383 ± 60       | 714 ± 328      | < .0001 |
| D-dimers (ng/ml)  | 92 ± 54        | 359 ± 296      | < .0001 |
| MPO-DNA (OD 405)  | 0.076 ± 0.024  | 0.518 ± 0.507  | < .0001 |
| DNA (mg/ml)       | 0.063 ± 0.027  | 0.463 ± 0.604  | < .0001 |
| Nucleosome (OD 405) | 0.128 ± 0.045 | 0.747 ± 0.62   | < .0001 |
| NE (ng/ml)        | 1.76 ± 0.27    | 2.99 ± 1.04    | < .0001 |
| TNM stage         |                |                |         |
| I                 | 7              | -              |         |
| II                | 9              | -              |         |
| III               | 25             | -              |         |
| IV                | 7              | -              |         |
| Differentiation   |                |                |         |
| Well              | -              | 3              | -       |
| Moderate          | -              | 9              | -       |
| Poor              | -              | 31             | -       |

CTR, healthy controls; GC, gastric cancer; TAT, thrombin-antithrombin complex; OD, optic density; MPO, myeloperoxidase; NE, neutrophil elastase; TNM, tumor-node-metastasis.
patients with GC were obviously higher than those in controls (713 ± 328 pg/ml, n = 48, vs. 383 ± 60 pg/ml, n = 36; 359 ± 296 ng/ml, n = 48, vs. 92 ± 54 ng/ml, n = 36, \( P < 0.0001 \) for both) (Table 1), suggesting a hypercoagulable state in the patients with GC.

**GC primes neutrophils to form NETs**

Since NETs play a potential role in linking sterile inflammation and venous thrombosis and contribute to coagulation activation [15-17], we assessed the potency of neutrophils isolated from patients with GC to form NETs. We observed that the number of ex vivo NET releasing neutrophils from patients with GC was significantly higher than that from control individuals, as demonstrated by NET formation in cells (7.1%, n = 48, vs. 3.4%, n = 36, \( P < 0.0001 \) (MPO/DNA counterstaining, Figure 1A-C) and extracellular DNA levels in isolated NET structures (1.92 ± 1.04, \( \mu \)g/ml, n = 48, vs. 0.49 ± 0.03, n = 36, \( P < 0.0001 \) (Figure 1D). To further illustrate whether the circulation environment of GC induces neutrophils to release NETs, we investigated the effects of plasma and platelets from patients with GC on neutrophil NET release in vitro. Following GC plasma or platelet stimulation, significant increases in NET formation in control neutrophils was observed compared to the baseline levels (Figure 2). However, the effect was not significant when compared to control neutrophils stimulated with healthy individual plasma or platelets (Figure 2).

**Procoagulant activity of NETs derived from patients with GC**

To study the procoagulant activity of NETs in patients with GC, thrombin levels and the

---

**Figure 1.** Enhanced neutrophil extracellular trap (NET) formation in neutrophils derived from patients with GC. (A) and (B). Representative microphotographs displaying NETs of neutrophils obtained from healthy controls and from patients with GC. Magnification, \( \times 200 \). Scale bars, 20 µm. (C) The percentage of extracellular trap-releasing neutrophils and (D) extracellular DNA levels significantly increase in patients with GC compared with healthy controls. *indicates \( P < 0.001 \). Results are expressed as means ± standard deviation. CTR, healthy control (n = 36); GC, gastric cancer (n = 48), MPO, myeloperoxidase; CFDNA, cell-free DNA.
potency of fibrin generation were assessed in control plasma treated with NETs. We observed significantly increased TAT levels after incubation of control plasma with NETs released by neutrophils isolated from GC compared with baseline (621 ± 164 pg/ml, vs. 380 ± 40 pg/ml, n = 48, P < 0.0001) (Figure 3A). However, TAT levels were not significantly increased after incubation of control plasma with NETs released by neutrophils isolated from healthy individuals (Figure 3A). Similarly, NETs released by neutrophils isolated from GC significantly increased the potency of fibrin generation in control plasma, as the time to peak and the peak turbidity of fibrin generation were significantly shorter and higher, respectively, than

Figure 2. The microenvironment in patients with GC primes control neutrophils to release neutrophil extracellular traps. A. Representative microphotographs showing neutrophil extracellular trap generation in control neutrophils treated with plasma and platelets obtained from control individuals or patients with GC, respectively. Original magnification: × 200. Scale bar: 20 μm. B-E. Percentage of extracellular trap-releasing neutrophils and extracellular DNA levels were respectively used for illustrating that the potency of plasma and platelets derived from patients with GC to induce control neutrophils (n = 5) to generate NETs were significantly higher than those from healthy controls. *P < 0.001. Results are expressed as means ± standard deviation. Plasma was respectively derived from 48 patients with GC and 36 healthy controls and platelets were respectively derived from 10 patients and 10 healthy controls. CTR, healthy control; GC, gastric cancer; CFDNA, cell-free DNA.
NETosis in gastric cancer

those in the baseline (Figure 3B, 3C). The effects of NETs released by neutrophils derived from controls on fibrin formation were not significant. To further certify a NET procoagulant role, we also performed an inhibition assay with DNase I. The results showed that treatment with DNase I significantly reduced the procoagulant role of NETs released by neutrophils derived from patients with GC (Figure 3D-F).

Increased NET formation in patients with GC

To further certify autonomous NET formation in patients with GC, we assessed the levels of circulating MPO-DNA complex, a well-established marker of NET formation [17, 33, 34]. We found that the amount of circulating MPO-DNA complex in patients with GC was significantly higher than that in healthy controls (OD 405 value, 0.518 ± 0.507, n = 48, vs. 0.076 ± 0.024, n = 36, P < 0.001) (Table 1). In addition, circulating MPO-DNA complex was significantly elevated with increased TNM stage (Figure 4) and positively correlated with TAT and D-dimers (Table 2). To further confirm NET formation in these patients, CFDNA, nucleosomes, and NE, all of which are utilized in NET production, were evaluated. We found that they all significantly increased in patients with GC compared with healthy controls and also increased in parallel with TNM stage elevation (Figure 4), and were positively correlated with TAT and D-dimer levels (Table 2). In contrast, NET formation was
NETosis in gastric cancer

not significantly correlated with tumor differentiation (not shown).

**NET contribution to fibrin generation in plasma from patients with GC**

To further certify that NETs contribute to the hypercoagulability in patients with GC, we investigated the role of NETs in the potency of autonomous plasma to generate fibrin. We found that the potency of GC plasma to generate fibrin significantly increased in patients with stage III/IV cancer compared with that of plasma from healthy controls (**Figure 5A, 5B**). Furthermore, treatment with DNase I significantly prolonged the time to peak and reduced peak turbidity in autonomous plasma derived from patients with GC and stage III/IV cancer (**Figure 5C, 5D**), whereas, the effect in patients with stage I/II cancer or healthy controls was not significant (**Figure 5C, 5D**). These data

**Figure 4.** Significant increase of NET formation in patients with GC. Myeloperoxidase-deoxyribonucleic acid complex (MPO-DNA), cell-free nucleosomes, and neutrophil elastase were measured with ELISA using plasma samples from healthy donors (CTR, n = 36), individuals with GC including patients in stage I (S-I, n = 7), stage II (S-II, n = 9), stage III (S-III, n = 25) and stage IV (S-IV, n = 7) cancer. Plasma CFDNA was quantified with fluorescent quantification. (A) MPO-DNA complex, (B) CFDNA, (C) nucleosomes, and (D) NE in patients with GC were increased with disease progression. Data are expressed as means ± standard deviation. *P < 0.001. GC, gastric cancer; OD, optical density; MPO, myeloperoxidase; CFDNA, cell-free DNA; NE, neutrophil elastase.
strongly suggest that NETs contribute to coagulation in patients with GC.

**Discussion**

Hypercoagulability contributes to a significantly increased morbidity and mortality in patients with cancer [8-10] and activated neutrophils play an important role in the thrombosis associated with cancer in animal models [23, 24]. Here, our results suggest that neutrophils derived from patients with GC display an enhanced ability to release NETs, which promote thrombin generation and then convert fibrinogen to fibrin. In addition, plasma or platelets derived from patients with GC stimulate control neutrophils to release NETs in vitro. We also identified that autonomous NET formation increased and contributed to the hypercoagulable state in patients with GC, whereas the procoagulant effect could be attenuated with DNase I dismantling of the NET structure. Furthermore, NET formation increased concomitant with TNM stage elevation and positively correlated with TAT and D-dimers levels.

NETs released from activated neutrophils were originally recognized as a host defense mechanism [35]. However, NET formation has also been shown to increase during sterile inflammation [17, 33, 34, 36-38]. In this study, we found that the ability of neutrophils isolated from patients with GC to extrude the DNA/MPO complex was significantly higher than that of neutrophils isolated from healthy controls, and that plasma or platelets isolated from these patients could induce control neutrophils to release NETs. Furthermore, autonomous NET formation in patients with GC was significantly higher than that in healthy controls. These data strongly support our assertion that NETs are spontaneously formed in patients with GC, which extends previous reports indicating that NETs form in patients with cancer plus thrombotic microangiopathies or thrombosis [28, 39].

In the present study, we found that plasma or platelets obtained from GC are able to induce control neutrophils to release NETs in vitro. Inflammation is a hallmark in cancer [21, 22] and significant increase of cytokines such as IL-8 or TNF-α, has been observed in patients with GC [40, 41]. Additionally, we have previously found that platelet activation increases in patients with GC, certified by increased phosphatidylserine-positive platelets and platelet-derived microparticles (unpublished). All these data suggest that GC induces a systemic environment to prime neutrophils to release NETs, and further supports previous opinion that cytokine and inflammatory factors as well as activated platelet-neutrophil interactions induce NET release [17, 33, 34, 38].

In this study, we also found that NETs released by neutrophils derived from GC significantly increased the potency of control plasma to generate thrombin and fibrin. Furthermore, the potency of plasma isolated from patients with stage III/IV GC to generate fibrin was attenuated with DNase I dismantling of NET structure. These results were consistent with and extend previous reports that NETs trigger coagulation activation [18]. In addition, research has also shown that cell-free histones, an important component of NETs, can cause activation of platelets and erythrocytes, which itself results in an increase in thrombin generation [19, 20]. Thus, NETs play at least a partial role in the coagulopathy of patients with GC.

Finally, we found that NET formation was significantly elevated in parallel with TNM stage increase. These data suggested that increased tumor burden caused enhanced NET formation. However, a recent study showed that NETs could trap circulating cancer cells and contribute to the homing of metastasis in mice with infections [42], and could modulate the immune response in Ewing sarcoma [43], and in addition that NE could promote tumor growth and metastasis in vivo and in vitro [44]. We specu-

<table>
<thead>
<tr>
<th>Variable</th>
<th>TAT (pg/mL)</th>
<th>D-dimers (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>P</td>
</tr>
<tr>
<td>CF-DNA</td>
<td>0.602 &lt; .0001</td>
<td>0.674 &lt; .0001</td>
</tr>
<tr>
<td>MPO-DNA (OD 405)</td>
<td>0.625 &lt; .0001</td>
<td>0.49 &lt; .0001</td>
</tr>
<tr>
<td>Nucleosomes (OD 405)</td>
<td>0.473 &lt; .0001</td>
<td>0.597 &lt; .0001</td>
</tr>
<tr>
<td>NE (ng/mL)</td>
<td>0.812 &lt; .0001</td>
<td>0.363 0.011</td>
</tr>
</tbody>
</table>

TAT, thrombin-antithrombin complex; CF-DNA, cell-free deoxyribonucleic acid; MPO, myeloperoxidase; OD, optic density; NE, neutrophil elastase.
late that NET formation and tumor progression might therefore create a vicious circle in patients with GC. Further research is needed to certify the role of NETs in cancer development.

In conclusion, hypercoagulability is a common aggravating factor that facilitates tumor progression and increases the risk of thrombosis [8-10]. In this study, we found that NETs contributed to the hypercoagulable state in patients with stage III/IV GC, and that the effect could be inhibited with DNase 1 treatment. Recent animal studies have shown that targeting NETs could alleviate a prothrombotic state, inhibit cancer metastasis, and ameliorate the organ dysfunction associated with cancer [24, 25, 42]. Accordingly, targeting NETs might attenuate the hypercoagulable state correlated with increased NET formation, which might in turn translate into a relative good prognosis for patients with GC.

Acknowledgements

We thank Dong Wang and Yan Xia for excellent technical assistance and editorial assistance from Editage. This work was supported by a Ministry of Education, “Chunhui Plan” research project (Z20100001).

Disclosure of conflict of interest

None.
NETosis in gastric cancer

Address correspondence to: Dr. Xiaoming Zou, Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Harbin Medical University, 246 Xuefu Street, Nangang District, Harbin 150001, China. Tel: 86 451 86605126; Fax: 86 451 86605126; E-mail: zou4930@163.com

References


NETosis in gastric cancer


NETosis in gastric cancer

